SuperworthBruker profit margin BRKR
Gross, operating and net profit as a share of revenue over the last twelve months, from 2010.
- Net margin, 12 months
- −2.0%
- Operating margin, 12 months
- −0.9%
- Net margin on a year earlier
- −4.3 pts
- Peer median
- 10.1%
Over the twelve months to Jun 30, 2026, Bruker kept −2.0% of its revenue as net profit, with an operating margin of −0.9% and a gross margin of 46.4%.
Five years earlier its net margin was 10.5%.
The median for 10 diagnostics and research stocks of a similar size is 10.1%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −0.3% | 2.0% | 45.9% |
| FY2024 | 3.4% | 7.5% | 49.0% |
| FY2023 | 14.4% | 14.7% | 51.0% |
| FY2022 | 11.7% | 17.1% | 51.6% |
| FY2021 | 11.5% | 17.1% | 50.0% |
| FY2020 | 7.9% | 12.5% | 47.3% |
| FY2019 | 9.5% | 14.5% | 48.0% |
| FY2018 | 9.5% | 13.8% | 47.5% |
| FY2017 | 4.5% | 12.4% | 46.2% |
| FY2016 | 9.5% | 11.0% | 46.1% |
| FY2015 | 6.3% | 9.0% | 43.6% |
| FY2014 | 3.1% | 5.8% | 42.2% |
| FY2013 | 4.4% | 8.1% | 43.8% |
| FY2012 | 4.3% | 8.7% | 46.3% |
| FY2011 | 5.6% | 9.4% | 45.6% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −2.0% | −4.3 pts | −0.9% | |
| Q1 FY26 | −0.3% | −2.6 pts | 1.3% | |
| Q4 FY25 | −0.3% | −3.6 pts | 2.0% | |
| Q3 FY25 | −0.6% | −10.0 pts | 1.9% | |
| Q2 FY25 | 2.3% | −9.0 pts | 5.3% | |
| Q1 FY25 | 2.3% | −11.1 pts | 6.4% | |
| Q4 FY24 | 3.4% | −11.1 pts | 7.5% | |
| Q3 FY24 | 9.4% | −1.9 pts | 8.8% | |
| Q2 FY24 | 11.3% | −0.5 pts | 10.9% | |
| Q1 FY24 | 13.4% | +1.5 pts | 12.6% | |
| Q4 FY23 | 14.4% | +2.7 pts | 14.7% | |
| Q3 FY23 | 11.3% | +0.4 pts | 16.5% |
Against its peers
Companies in Medical - Diagnostics & Research nearest Bruker's size, closest first, today.
| Company | Profit margin |
|---|---|
| BRKRBruker | −2.0% |
| CAICaris Life Sciences | 10.6% |
| BIOBio-Rad Laboratories | 8.6% |
| LNTHLantheus | 17.7% |
| BLLNBillionToOne | 9.5% |
| RVTYRevvity | 8.2% |
| MEDPMedpace | 17.7% |
| VCYTVeracyte | 20.4% |
| CDNACareDx | 24.2% |
| LHLabcorp | 7.0% |
| DGXQuest Diagnostics | 9.2% |
| Peer median | 10.1% |
Where Bruker ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Bruker
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.